G2019S-LRRK2 mutation enhances MPTP-linked Parkinsonism in mice.
Parkinson's disease (PD) is a common neurodegenerative disease with a heterogeneous etiology that involves both genetic and stress insults. Current LRRK2 PD animal models are only partly reproducing the characteristics of the disease with no or very subtle dopaminergic neuron degeneration. We developed a new model of PD that combines a sub-toxic MPTP insult to the G2019S-LRRK2 mutation. Our newly generated mice, overexpressing mutant G2019S-LRRK2 protein in the brain, displayed a mild, age-dependent progressive motor impairment, but no reduction of lifespan. Cortical neurons from G2019S-LRRK2 mice showed an increased vulnerability to various stress insults compared to neurons overexpressing wild type WT-LRRK2, or non-transgenic neurons. The exposure of LRRK2 transgenic mice to a subtoxic dose of MPTP resulted in severe motor impairment, selective loss of dopamine neurons and increased astrocyte activation, whereas non- transgenic mice with MPTP exposure showed no deficits. Interestingly, mice overexpressing WT-LRRK2 showed a significant impairment that was milder than for the mutant G2019S-LRRK2 mice. L-DOPA treatments could partially improve the movement impairments, but did not protect the dopamine neuron loss. In contrast, treatments with a LRRK2 kinase inhibitor, significantly reduced the dopaminergic neuron degeneration in the gene mutation and MPTP interaction model. Our studies provide a novel LRRK2 gene-MPTP interaction PD mouse model, which may reflect a more natural progression of LRRK-linked PD. This model provides a useful tool for future studies of PD pathogenesis and therapeutic intervention.